Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection

Clinical features of Coronavirus disease 2019 (COVID-19) are caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Acute infection management is a substantial healthcare issue, and the development of long-Covid syndrome (LCS) is extremely challenging for patients and physicians. It...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bettina Hohberger, Thomas Harrer, Christian Mardin, Friedrich Kruse, Jakob Hoffmanns, Lennart Rogge, Felix Heltmann, Michael Moritz, Charlotte Szewczykowski, Julia Schottenhamml, Martin Kräter, Antonio Bergua, Matthias Zenkel, Andreas Gießl, Ursula Schlötzer-Schrehardt, Robert Lämmer, Martin Herrmann, Annekathrin Haberland, Peter Göttel, Johannes Müller, Gerd Wallukat
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	functional GPCR autoantibodies COVID-19 long-COVID syndrome chronic fatigue syndrome BC 007 OCT angiography Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c58ca098cedc4a768c86c2e58b7b46c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c58ca098cedc4a768c86c2e58b7b46c2
record_format	dspace
spelling	oai:doaj.org-article:c58ca098cedc4a768c86c2e58b7b46c22021-11-18T09:48:52ZCase Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection2296-858X10.3389/fmed.2021.754667https://doaj.org/article/c58ca098cedc4a768c86c2e58b7b46c22021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.754667/fullhttps://doaj.org/toc/2296-858XClinical features of Coronavirus disease 2019 (COVID-19) are caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Acute infection management is a substantial healthcare issue, and the development of long-Covid syndrome (LCS) is extremely challenging for patients and physicians. It is associated with a variety of characteristics as impaired capillary microcirculation, chronic fatigue syndrome (CFS), proinflammatory cytokines, and functional autoantibodies targeting G-protein-coupled receptors (GPCR-AAbs). Here, we present a case report of successful healing of LCS with BC 007 (Berlin Cures, Berlin, Germany), a DNA aptamer drug with a high affinity to GPCR-AAbs that neutralizes these AAbs. A patient with a documented history of glaucoma, recovered from mild COVID-19, but still suffered from CFS, loss of taste, and impaired capillary microcirculation in the macula and peripapillary region. He was positively tested for various targeting GPCR-AAbs. Within 48 h after a single BC 007 treatment, GPCR-AAbs were functionally inactivated and remained inactive during the observation period of 4 weeks. This observation was accompanied by constant improvement of the fatigue symptoms of the patient, taste, and retinal capillary microcirculation. Therefore, the removal of GPCR-AAb might ameliorate the characteristics of the LCD, such as capillary impairment, loss of taste, and CFS.Bettina HohbergerThomas HarrerThomas HarrerChristian MardinFriedrich KruseJakob HoffmannsLennart RoggeFelix HeltmannMichael MoritzCharlotte SzewczykowskiJulia SchottenhammlMartin KräterMartin KräterAntonio BerguaMatthias ZenkelAndreas GießlUrsula Schlötzer-SchrehardtRobert LämmerMartin HerrmannMartin HerrmannAnnekathrin HaberlandPeter GöttelJohannes MüllerGerd WallukatFrontiers Media S.A.articlefunctional GPCR autoantibodiesCOVID-19long-COVID syndromechronic fatigue syndromeBC 007OCT angiographyMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	functional GPCR autoantibodies COVID-19 long-COVID syndrome chronic fatigue syndrome BC 007 OCT angiography Medicine (General) R5-920
spellingShingle	functional GPCR autoantibodies COVID-19 long-COVID syndrome chronic fatigue syndrome BC 007 OCT angiography Medicine (General) R5-920 Bettina Hohberger Thomas Harrer Thomas Harrer Christian Mardin Friedrich Kruse Jakob Hoffmanns Lennart Rogge Felix Heltmann Michael Moritz Charlotte Szewczykowski Julia Schottenhamml Martin Kräter Martin Kräter Antonio Bergua Matthias Zenkel Andreas Gießl Ursula Schlötzer-Schrehardt Robert Lämmer Martin Herrmann Martin Herrmann Annekathrin Haberland Peter Göttel Johannes Müller Gerd Wallukat Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection
description	Clinical features of Coronavirus disease 2019 (COVID-19) are caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Acute infection management is a substantial healthcare issue, and the development of long-Covid syndrome (LCS) is extremely challenging for patients and physicians. It is associated with a variety of characteristics as impaired capillary microcirculation, chronic fatigue syndrome (CFS), proinflammatory cytokines, and functional autoantibodies targeting G-protein-coupled receptors (GPCR-AAbs). Here, we present a case report of successful healing of LCS with BC 007 (Berlin Cures, Berlin, Germany), a DNA aptamer drug with a high affinity to GPCR-AAbs that neutralizes these AAbs. A patient with a documented history of glaucoma, recovered from mild COVID-19, but still suffered from CFS, loss of taste, and impaired capillary microcirculation in the macula and peripapillary region. He was positively tested for various targeting GPCR-AAbs. Within 48 h after a single BC 007 treatment, GPCR-AAbs were functionally inactivated and remained inactive during the observation period of 4 weeks. This observation was accompanied by constant improvement of the fatigue symptoms of the patient, taste, and retinal capillary microcirculation. Therefore, the removal of GPCR-AAb might ameliorate the characteristics of the LCD, such as capillary impairment, loss of taste, and CFS.
format	article
author	Bettina Hohberger Thomas Harrer Thomas Harrer Christian Mardin Friedrich Kruse Jakob Hoffmanns Lennart Rogge Felix Heltmann Michael Moritz Charlotte Szewczykowski Julia Schottenhamml Martin Kräter Martin Kräter Antonio Bergua Matthias Zenkel Andreas Gießl Ursula Schlötzer-Schrehardt Robert Lämmer Martin Herrmann Martin Herrmann Annekathrin Haberland Peter Göttel Johannes Müller Gerd Wallukat
author_facet	Bettina Hohberger Thomas Harrer Thomas Harrer Christian Mardin Friedrich Kruse Jakob Hoffmanns Lennart Rogge Felix Heltmann Michael Moritz Charlotte Szewczykowski Julia Schottenhamml Martin Kräter Martin Kräter Antonio Bergua Matthias Zenkel Andreas Gießl Ursula Schlötzer-Schrehardt Robert Lämmer Martin Herrmann Martin Herrmann Annekathrin Haberland Peter Göttel Johannes Müller Gerd Wallukat
author_sort	Bettina Hohberger
title	Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection
title_short	Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection
title_full	Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection
title_fullStr	Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection
title_full_unstemmed	Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection
title_sort	case report: neutralization of autoantibodies targeting g-protein-coupled receptors improves capillary impairment and fatigue symptoms after covid-19 infection
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c58ca098cedc4a768c86c2e58b7b46c2
work_keys_str_mv	AT bettinahohberger casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT thomasharrer casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT thomasharrer casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT christianmardin casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT friedrichkruse casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT jakobhoffmanns casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT lennartrogge casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT felixheltmann casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT michaelmoritz casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT charlotteszewczykowski casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT juliaschottenhamml casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT martinkrater casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT martinkrater casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT antoniobergua casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT matthiaszenkel casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT andreasgießl casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT ursulaschlotzerschrehardt casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT robertlammer casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT martinherrmann casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT martinherrmann casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT annekathrinhaberland casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT petergottel casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT johannesmuller casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection AT gerdwallukat casereportneutralizationofautoantibodiestargetinggproteincoupledreceptorsimprovescapillaryimpairmentandfatiguesymptomsaftercovid19infection
_version_	1718420870149439488

Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection

Ejemplares similares